The SFTPC gene gives the lungs instructions to make surfactant protein C, a substance that helps keep the tiny air sacs open so breathing is easier. This gene plays an important role in the thin lining of the lungs, where surfactant helps air move in and out smoothly. If a harmful variant affects how the protein is made or folded, some people develop interstitial lung disease, with symptoms such as fast breathing, cough, or low oxygen. Effects can begin in infancy or later in life, and severity varies widely.
What is a gene?
Genes are stretches of DNA that hold instructions your cells use to make molecules or regulate processes throughout the body. Some carry the directions for building proteins, which do much of the cell’s work. Others mainly help determine when certain processes happen, where they take place, and how active they are. Taken together, genes affect how your body develops and works, and they can influence how you respond to food, stress, and medications. To go deeper into this topic, you can learn more in LearnHub.
Overview
SFTPCGene function
What if the gene works
The SFTPC gene gives instructions for surfactant protein C, made in tiny air sacs in the lungs. This protein helps lower surface tension so the air sacs stay open and breathing stays easier.
Risk
What if the gene does not work
Variants in the SFTPC gene can disrupt surfactant, which helps keep air sacs open. This may cause lung disease, from newborn breathing distress to childhood or adult interstitial lung disease. Milder and more severe variants can affect timing and severity.
Treatment
What does that mean for your treatment
No treatment or drug choice is currently tailored specifically to pathogenic or loss-of-function variants in the SFTPC gene in clinical guidelines. The SFTPC gene is being studied as a driver of surfactant-related lung disease, and medicines such as hydroxychloroquine have been explored in selected cases, but this is not an established gene-specific standard.
Conditions associated with SFTPC
Gene function
What if the gene works
Breathing depends on a thin, slippery coating inside the tiny air sacs of the lungs. The SFTPC gene helps specialized lung cells make surfactant protein C, an important part of that coating. When this system works as expected, the air sacs stay more stable with each breath.
Specialized cells in the lungs use the SFTPC gene to make surfactant protein C. This protein becomes part of the surfactant layer that coats the tiny air sacs.
Surfactant protein C helps the surfactant layer spread evenly as you breathe in and out. This lowers surface tension (the pull that can make wet surfaces stick), which is a key part of normal SFTPC gene function in the lungs.
By supporting the surfactant layer, this protein helps keep the smallest air spaces open, especially after breathing out. That helps the lungs work smoothly across millions of tiny air sacs.
What is a variant?
A genetic variant is a slight change in the DNA sequence of a gene. These changes are common and are part of normal human diversity, including differences in appearance, metabolism, and how the body responds to environmental influences. Many variants do not have any noticeable effect and simply represent natural genetic variation. In some situations, though, a variant can change how a gene functions more substantially and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Variants in the SFTPC gene often change how surfactant protein C is folded and processed inside lung cells, shaping how SFTPC gene variants affect protein function. Misfolded protein may get trapped, build up, and stress the cells, and some variants also lower the amount of mature protein that reaches the air sacs. Milder variants may cause smaller processing changes, while more severe variants can lead to greater cell injury and are often linked to earlier or marked interstitial lung disease.
How variants are linked to conditions
Pathogenic variants in the SFTPC gene can cause inherited lung conditions, most often forms of interstitial lung disease, where the lungs become inflamed or scarred. People may develop breathing problems soon after birth, ongoing childhood lung disease, or, in some families, pulmonary fibrosis in adulthood. A confirmed disease-causing SFTPC variant can help establish the diagnosis.
A variant is not necessarily a diagnosis
Genetic variants are a common and normal feature of human biology. Most do not directly affect health and simply contribute to natural differences among people. For many genes, having a variant associated with a condition points to a possible link rather than a confirmed diagnosis, particularly when several genes and environmental influences play a role. In other situations, one well-characterized variant in a particular gene is enough to confirm a diagnosis.
Are there things that can increase or change my risk?
For SFTPC, the main driver of risk is the gene change itself, and symptoms can vary widely even within the same family. Lung irritants such as cigarette smoke, vaping, and repeated chest infections may worsen breathing problems, but there is not enough evidence to say they change whether the condition starts. Anyone worried about personal risk can talk with a doctor or genetic counselor.
Inheritance of SFTPC variants
Variants in the SFTPC gene are usually inherited in an autosomal dominant pattern, which means a child can inherit the gene change from one affected parent. If a parent carries an SFTPC variant linked to disease, each child has a 50% chance of inheriting it. In understanding how variants of the SFTPC gene are inherited, it also helps to know that some people have a new, de novo variant that was not inherited from either parent. Sons and daughters are affected equally.
What does my SFTPC result mean for my family?
A harmful change in the SFTPC gene is usually passed in a dominant pattern, so close relatives such as a parent, brother, sister, or child may also carry the same change. In some families, more than one person has lung disease, while in others a relative may carry the change and have milder symptoms or none that are obvious. Some SFTPC changes happen for the first time in one person, so a parent is not always the source.
Genetic information
Genetic testing
How you find out about variants
To find out whether you carry a variant in the SFTPC gene, doctors may use SFTPC gene testing for interstitial lung disease with a blood or saliva sample. A lab reads the DNA sequence and compares it with the usual pattern to look for variants that may help explain symptoms or support a diagnosis.
When should I consider getting a genetic test?
Consider testing for the SFTPC gene if a baby, child, or adult has unexplained ongoing lung disease, especially lung scarring or repeated breathing problems, or if these problems run in the family. A result can help explain the cause and whether relatives may also be affected.
A genetic result is only one part of your health story
Genetic findings can be very informative, but how much they explain varies by the condition and the type of variant involved. Over time, many factors, including lifestyle, environment, age, and medical history, influence how the body functions. In some conditions, especially those shaped by many genes, genetic information offers context rather than certainty and is best considered alongside other parts of care. In other situations, a genetic result may give a clear answer. In areas like medication response, genetic results can also help make individual experiences easier to understand.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. This helps explain why the same treatment works well for one person, seems less helpful for another, or causes more side effects in someone else. Differences in how the body handles a drug and how sensitive the body is to its effects are common, and they can influence both benefit and tolerance.
What is Pharmacogenetics?
Pharmacogenetics focuses on how differences in genes can shape the way someone responds to a medication. It examines links between genes and drugs to help explain why the same treatment may work differently in different people. With many medications, genes can influence either how powerfully a drug works or how the body handles it. This information can support treatment choices that are both more informed and more personalized. More on this topic is available in the LearnHub.
Drugs influenced by the SFTPC gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding how medicines are chosen or used. Questions about symptoms, lung health, or any medicine concerns are best discussed with your doctor.
History
The SFTPC gene entered medical genetics through research on unexplained lung disease in newborns, children, and adults from the same families. In the early 2000s, researchers identified variants in the SFTPC gene in families with inherited interstitial lung disease, helping connect a long puzzling pattern of breathing illness across generations. Initially understood only through visible traits, later recognized as tied to a specific gene, these findings changed how some familial lung conditions were classified. From these first observations, research expanded steadily, and clinicians began to recognize that changes in this gene could appear at very different ages. That history helped move care from describing lung scarring by appearance alone toward a clearer genetic diagnosis in some families.